🇺🇸 Ultragenyx Pharmaceutical Inc.RARE

Company Update Form 8-K 07-10-2026 09:00:14 EDT

Subject: 8-K Items 1.01

Overview: Entered into an asset purchase agreement on October 6, 2026, to sell a Rare Pediatric Disease Priority Review Voucher for $210 million in cash.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest